Primary Objectives:
1. To determine the patient's tumor response rate that this protocol will produce.
2. To determine the 1 year progression-free survival that this protocol will produce.
Secondary Objective:
1. To determine whether antibody-dependent cell-mediated cytotoxicity (ADCC) is the mechanism
of overcoming Herceptin-resistance by use of Granulocyte-Macrophage Colony Stimulating Factor
(GM-CSF).